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Cyclosporin A
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The epidermal serine proteinase inh ib itor SKAUP 
(also known as elafin), directed against hum an leu k o ­
cyte elastase and proteinase 3, is strongly in d u ced  in  
suprabasal keratinocytes during in flam m ation . T he  
presence o f  SKALP/elafin in urine has b een  d em on ­
strated for several inflam m atory skin disorders, such  
as psoriasis, erythroderma, and erysipelas. In this 
study w e investigated w hether SKALP/elafin levels in  
serum and urine o f  psoriatic patients can b e  used  as a 
marker for disease activity during treatm ent. Patients  
with severe chronic disabling psoriasis w ere treated  
for 16 weeks w ith cyclosporin A, w hich  resu lted  in  a 
marked clinical im provem ent as m easured w ith  the  
PASI score. SKALP/elafin levels both  in serum  and  
urine were determ ined w ith  an en zym e-lin k ed  im ­
e have recently shown that skin-derived 
antileukoproteinase (SKALP), a serine pro­
teinase inhibitor virtually absent in normal 
epidermis, is induced in lesional psoriatic 
skin [1], We found that SKALP, also known 
as elafin [2,3], is not specific for psoriasis, but can be considered as 
one of the markers of the regenerative differentiation program that 
is also found in other conditions such as wound healing [4,5] and 
several inflammatory skin diseases [6]. SKALP/elafin is a strong 
inhibitor of the leukocytic enzymes elastase [1] and proteinase-3
[7], and is putatively involved in the regulation of cutaneous 
inflammation. In previous studies SKALP/elafin was described 
biochemically [8] and characterized at the protein and DNA level 
[9]. We established the cellular source and localization in psoriatic 
epidermis [10], and we found that SKALP/elafin is differentially 
expressed in human epidermal tumors [11]. Recently we have been 
able to assign the SKALP/elafin gene to chromosome region 
20ql2-ql3 [12]. The gene has been given the approved name of 
Pro tease Inhibitor, skin-derived (SKALP) and the symbol PI3 in the 
Genome Data Base of the HUGO nomenclature committee.
In psoriasis, SKALP/elafin is expressed in the upper spinous 
layers of lesional skin [10]. We showed that SKALP/elafin as
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m unosorbent assay (ELISA). M easurem ents were per« 
form ed  at the start o f  the cyclosporin  A treatm ent, 
and after regular intervals up to 16 w eeks. T he results 
in d icate  that 1) SKALP/elafin determ ination  in serum  
rather than in urine is the preferred m eth od , because  
the decrease in  serum SKALP levels during therapy is 
m ore pronounced and correlated b etter w ith the  
clin ica l course o f  the patients; 2) SKALP/elafin levels  
in  serum  decreased during cyclosporin  A treatm ent 
(p < 0.05); and 3) SKALP/elafin levels in  serum  cor­
relate with the PASI score (p <  0.01). W e con elude  
that SKALP/elafin m easurem ent in serum  o f  patients 
w ith  severe psoriasis provides a tool for m onitoring  
disease activity. Keywords: ELISAlproteinase inhibitor! 
epidermis. J  Invest Dermatol 104:189-193, 1995
expressed in cultured epidermal keratinocytes is translated as a 
12.3-kDa protein. Cleavage of the signal peptide yields a 9.9-kDa 
protein that is the major form found in cultured cells, as was 
confirmed by purification and N-temiinal amino acid sequencing
[9]. The presence of a signal peptide suggests that SKALP/elafin is a 
secreted protein. We indeed found that significant amounts of biolog­
ically active SKALP/elafin can be found in die urine of psoriatic 
patients [13], a finding that was recently confirmed by others [14]. In 
urine of healthy individuals SKALP/elafin was not detectable. Appar­
ently, once secreted in the epidermis, SKALP/elafin is able to reach 
the circulation, and is subsequently cleared via the kidney. Although 
we were then not able to measure SKALP/elafin in serum, this was a 
likely route, because SKALP/elafin is a low-molecular-weight cat­
ionic protein that will easily cross basal membranes.
In the present study there were two objectives: first, we wanted 
to develop an assay for SKALP/elafin assessment in serum of 
psoriatic patients, and second we wanted to investigate if measure­
ment of SKALP/elafin in urine and serum could b e used as a marker 
for disease activity during therapy. In our previous study, we used 
a functional biochemical assay to measure SKALP/elafin in urine
[13]. However, in serum this is not possible due to interfering 
factors. We therefore developed an enzyme-linked immunosorbent 
assay (ELISA) that allows measurement of SKALP/elafin both in 
serum and in urine. Using this ELISA we found that patients with 
severe psoriasis during therapy with cyclosporin A (CyA) showed a 
decrease of SKALP/elafin activity in serum that correlated with a 
decrease in clinical scores (psoriasis area and severity index (PASI) 
score). These findings suggest that SKALP/elafin can be used as a
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marker for disease activity and can be used as a quantitative 
measure to monitor therapeutic effects.
MATERIALS AND METHODS
Chemicals Tween~20 was obtained from Merck, Schuchardt, Hohen- 
brunn bei Munich, Germany, and bovine serum albumin (BSA) from 
Organon Teknika, Box tel, The Netherlands. Swine-anti-rabbit peroxidase 
was obtained from Dako, Copenhagen, Denmark, and o-phenyl- 
enediamine.2HCl from Pierce, Rockford, IL. Microtiter plates (96 cells) for 
ELISA were obtained from Greiner, Alphen a/d Rijn, The Netherlands. 
Recombinant SKALP/elafin was a kind gift from Dr. Norman Russell, ICI 
Pharmaceuticals, UK.
Subjects, Sam ple C ollection  and Preparation Fifteen healthy volun­
teers (5 male, 10 female, ages 2—79 years) took part in the experiments to 
study age or sex differencess in SKALP/elafin serum levels. For determina­
tion of circadian variation blood was drawn every 4 h during 24 h in a 
psoriatic patient and a healthy control. Six male patients (ages 36—64 years, 
mean age 48 years) with severe chronic disabling psoriasis participated. 
Patients had not used any systemic treatment for at least 4 weeks or local 
treatment for at least 1 week prior to the start of CyA therapy. In all patients, 
initial dosage of CyA was 3 mg/kg body weight; in two patients this dosage 
was increased up to 4 mg/kg body weight after 8 weeks of treatment. 
Before treatment, disease activity was evaluated and expressed using the 
PASI score. This scoring system estimates disease activity depending on 
erythema, infiltration, desquamation, and the area of the psoriatic skin that 
is affected [15]. At the start of CyA therapy, and after 2, 4, 8, 12, and 16 
weeks, samples of blood and urine were taken, and a PASI score as measure 
of disease activity. Samples of blood and urine were frozen and stored at 
—20oC until measurement of SKALP/elafin.
Anti-SKALP/Elafin Serum Recombinant SKALP/elafin was used fori
immunization procedures as described before [8], In short, a rabbit was 
immunized intracutaneously with recombinant SKALP/elafin that was 
crosslinked with glutaraldehyde and emulsified in Freund’s complete adju­
vant. A booster with the same preparation was given after 2 weeks, and 4 
weeks later serum was collected via standard methods. Control (pre- 
immune) serum was drawn before the immunization procedure. The 
specificity of the antiserum was validated as described before [8].
ELISA To measure SKALP/elafin concentrations in serum and urine of 
psoriatic patients, we used a competitive-type ELISA. Blood samples were 
taken, coagulated for 60 min at room temperature, and centrifuged at 450 
X ^for 10 min. Serum was acidified to a final concentration of 0.05 N HC1, 
boiled for 2 min, and centrifuged for 60 min (2000 X ¿r, 4°C). Urine was 
boiled for 2 min, cooled on ice for 30 min, and centrifuged for 15 min (2000 
X g , 4°C). Creatinine measurement was done before by an alkaline picrate 
determination with kinetic endpoint detection, and carried out with re­
agents from Boehringer Mannheim using a Hitachi 747 analyzer, Superna- 
tants were taken for quantification of SKALP/elafin.
The supematants were mixed to contain 80% supernatant, 0.1 M Tris, 
0.1% Tween-20, 1% BSA, and rabbit anti-SKALP/elafin antiseruni (1:9500 
diluted), and incubated overnight. Microtiter plates (96 flat-bottom wells) 
were coated overnight with 50 ng/ml recombinant SKALP/elafin in 
phosphate-buffered saline (PBS). After washing of the plates with PBS/ 
0.05% BSA, micro titer plates were blocked, probed with the test samples, 
and developed during 60 min with swine anti-rabbit peroxidase using 
o-phenylenediamine.2HCl as chromo genic substrate for 30 min. Human 
recombinant SKALP/elafin in PBS with 0.1% BSA was used as a standard: 
a calibration curve was made, using recombinant SKALP/elafin in the range 
of 0.6-80 ng/ml. The SKALP/elafin concentrations in serum or urine 
samples were read from this curve. All ELISA steps were performed at 4°C, 
except development with o-phenylenediamine.2HCl, which was done at 
room temperature. Data were read with a Biorad ELISA-reader, and 
evaluated using the Excell spread sheet program.
Statistical Analysis Regression analysis was performed to correlate 
SKALP/elafin levels in serum and urine with each other, with time of CyA 
treatment, and with the disease activity as expressed in the PASI score. 
Mean r (Pearson moment product correlation) was obtained after Fisher-z 
transformation.
RESULTS
PASI Score and CyA Treatment All patients showed good 
clinical improvement during 16 weeks of treatment with CyA» and 
apart from slight gastrointestinal discomfort no complaints were 
reported. Mean PASI score was 20.0 (10.6-36.0) at the start of the 
treatment, and decreased to 3.4 (2.0—5.4) at week 16. In two
patients dosage of CyA was increased at week 8 due to lack of 
clinical progress. Using routine blood tests for liver and kidney 
functions, no side effects on these organs could be demonstrated; 
one patient showed hypertrichosis. Urine and blood samples of one 
of the patients could not be taken until 2 weeks after the start of the 
CyA treatment.
Sensitivity and Accuracy of the ELISA The ELISA we de­
veloped is of the competitive type, based on the displacement of a 
defined amount of recombinant SKALP/elafin by SKALP/elafin in 
the urine or serum samples. A calibration curve from which the 
sample values are read in the interval between 3—40 ng per ml is 
given in Fig 1. The detection limit is 3 ng/ml.
Experiments to check the recovery of recombinant SKALP/ 
elafin added to normal human serum revealed that recovery is 
temperature dependent (not shown). When the ELISA was per­
formed at 4°C a recovery of 100% was found (Fig 2). Figure 2 also 
shows that a pool of normal human serum has a background level 
of SKALP/elafin, which appeared to be about 9 ng/ml (intercept of 
the Y-axis). The standard deviation of measurements in quadrupli­
cate was within 10%.
SKAJLP/Elafin Measurement in Urine SKALP/elafin levels 
were expressed in ng/ml urine, and corrections for creatinine 
concentrations were made. SKALP/elafin levels in urine varied 
from 3 ng/ml up to more than 120 ng/ml (Fig 3). Five of six 
patients showed a clear decrease in urinary SKALP/elafin levels. 
One patient showed extremely low values of creatinine concentra­
tion, which had an enormous impact on correction for creatinine 
(Fig 3c); note that his serum level of SKALP/elafin decreased 
during treatment (Fig 4c). Decrease of SKALP/elafin levels in urine 
during treatment was statistically significant (Fisher-z, p < 0.05).
Urinary SKALP/elafin levels decreased, but were not found 
below 3 ng/ml. Healthy controls do show a similar amount of 
SKALP/elafin in urine (data not shown), and 3-10 ng/ml may be 
regarded as a normal background level of SKALP/elafm in human 
urine.
SKAJLP/Elafin Measurement in Serum Serum levels for 
SKALP/elafin were measured in 15 healthy volunteers. No effect o f 
age on SKALP/elafin levels was found (not shown). A small 
difference in SKALP/elafin serum levels (ng/ml) was found be­
tween male (14.6 ± 2.6) and female (8.5 ± 6.1). No circadian 
rhythm was observed (not shown). SKALP/elafin levels in psoriatic 
patients varied from 11 ng/ml up to more than 300 ng/ml (Fig 4). 
These levels significantly decreased during treatment with CyA 
(Fisher-z, p <  0.05) and correlated well with clinical improvement 
as expressed in the PASI score (Fisher-z, p < 0.01). This decrease 
in SKALP/elafin level was found in the serum of all six patients. 
SKALP/elafin levels in serum were about sixfold higher than in
n
urine, and levels in serum were positively correlated with levels in 
urine (Fisher-z, p < 0.01).
80 40 20 10 5 2.5 1.25 0.«25 0.313
SKALP (no/ml)
F igure 1. Calibration curve o f  recom binant SKALP/elafin. A
sigmoid relationship between the ELISA signal and the SKALP/elafin 
concentration of the samples is found. The useful range for measurement o f 
SKALP/elafin concentrations is between 3 and 40 ng/ml.
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Figure 2. Mean values ±  2 SD o f  measurements in  quadruplicate o f  
three concentrations o f  recom binant SKALP/elafin in normal h u ­
man serum. SD is 10%. The intercept with the Y-axis indicates that in 
humans a background serum level of SKALP/elafin appears to be present. 
This background level is about 9 ng/ml.
DISCUSSION
Increased amounts of SKALP/elafin have been demonstrated in 
urine of patients with psoriasis [13] and several other inflammatory 
skin diseases [14]. Because SKALP/elafin is barely detectable in 
normal skin and is strongly expressed in inflamed skin, we hypoth­
esized that the increase in urinary SKALP/elafin in psoriatics is 
derived from local production in skin. This would be in line with 
the fact that SKALP/elafin is a secreted molecule [16] and the 
notion that epidermis acts as a secretory organ as recently described 
[17,18]. However, no definitive proof could be given for the 
epidermal origin of urinary SKALP/elafin in psoriatic patients,
because SKALP/elafin could not be demonstrated in the interme­
diate compartments between epidermis and urine (i.e., dermis and 
blood). In our initial study we used a functional assay to measure 
SKALP/elafin, that could not be applied to serum, due to interfer­
ence by the overwhelming amount of other plasma-derived pro­
teinase inhibitors.
Intraepidermal accumulation of PMN is an early event in the 
pathogenesis of the psoriatic lesion [19], and PMN-derived pro- 
teinases were shown to degrade the dermo-epidermal junction in 
vitro [20]. This suggests that elastase may be involved in PMN 
migration and PMN-dependent tissue damage and may promote 
the inflammatory response. Several antipsoriatic therapies are 
known to interfere with this PMN migration, suggesting that they 
are involved in the downregulation of inflammation [21]. In 
addition to proteinases from inflammatory cells, keratinocyte- 
derived proteinases such as plasminogen activator may act as a 
pro-inflammatory mediator in psoriatic skin [22]. Synthesis of 
proteinase inhibitors that counteract proteinases by forming inac­
tive complexes is one of the in vivo mechanisms to protect tissue 
against unwanted proteolysis [23]. These proteinase inhibitors may 
be present in plasma, or can be produced locally at the site of action 
[8,24,25]. Complexes between elastase and elastase inhibitors in 
serum, sputum, broncho alveolar lavage, and urine have been 
described, the inhibitors being al-PI [26-28], antileukoproteinase 
[29], or SKALP/elafin [13]. Levels of these complexes may be 
related to disease activity, and measurement may provide a tool for 
monitoring therapeutic result. Increased levels of complexes be­
tween elastase and inhibitors, but also of free elastase or free 
inhibitor, have been reported in lung cancer [30], neonatal systemic 
infection [31,32], adult respiratory distress syndrome [27,32], cer­
vical cancer [33,34], psoriasis, eczema, and other cutaneous disor-
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Figure 3. SKALP/elafin levels in urine of* six psoriatic patients (a - j)  during treatment w ith  CyA. SKALP/elafin levels (ng/ml) are shown before 
(open squares) and after correction for creatinine concentration (solid squares). Decrease of SKALP/elafin levels in urine is statistically significant (Fisher z,
p <  0.05).
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ders [35-37], and these levels can be used as parameters for 
monotoring disease activity.
In normal epidermis, anti-elastase activity is hardly detectable 
[1], although the presence of al-PI and a2  macro globulin in 
normal skin has been described [38,39]. Teleologically, it is plau­
sible that after a disturbance of the proteinase-antiproteinase bal­
ance in skin, resulting in an excess of elastase, SKALP/elafin is 
produced to limit proteolytic action of this leukocytic proteinase. 
After a period of proteolysis by elastase a rebalancing takes place, 
and SKALP/elafin molecules may temporarily outnumber elastase 
molecules. Complexes are secreted in urine [13], but epidermic 
clearance via loss of scales that contain complexes may take place as 
well. Finally, restoration of normal homeostasis is followed by an 
off-switch of SKALP/elafin production by the epidermal cells.
Using a competitive-type ELISA, we were able to demonstrate 
the presence of SKALP/elafm in serum of normal individuals and 
psoriatic patients. The assay was found to be reproducable and 
reasonably sensitive (detection limit 3 ng/ml). We found a back­
ground level of SKALP/elafin in serum of healthy controls and 
symptom-free psoriatic patients that is probably derived from the 
turnover in tissues where SKALP/elafin is constitutively expressed. 
We have recently completed a survey of SKALP/elafin in normal 
human epithelia (Aikemade et al, manuscript in preparation) and 
found that the molecule is expressed in a limited number of normal 
tissues. This background level of SKALP/elafm in serum negatively 
influences the sensitivity of the assay for detecting an increase in 
inflammatory skin diseases.
In severe psoriatic patients with a large area of involved skin, 
serum levels are significantly higher than in healthy controls and 
symptom-free psoriatic patients. It is shown that during therapy 
with CyA, which is a potent antipsoriatic drug, serum levels
gradually decrease and stabilize to a level that is still higher than in 
normal controls. This decrease in SKALP/elafin levels correlates 
with the decrease in PASI scores, and we assume that the decrease 
in serum SKALP/elafin levels during therapy reflects the rate of 
normalization of the epidermis. The SKALP/elafin concentrations 
in serum were about sixfold higher than in urine, and the decrease 
in serum during treatment was more impressive and correlated 
better with the clinical course. Therefore, determination of 
SKALP/elafin in serum rather than in urine was considered to be 
the method of preference. Because SKALP/elafin levels correlated 
well with the clinical state as represented by the PASI score, we 
conclude that SKALP/elafin measurement in serum of patients with 
severe psoriasis provides a tool for monitoring disease activity.
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